Somatostatin analogs (SSA) are well-established antisecretory drugs in functionally active
neuroendocrine tumors (NET). Two placebo-controlled trials have recently demonstrated …

Introduction The expression and reliable detection of somatostatin receptor subtypes
(SSTR1–5) is a prerequisite for the successful use of somatostatin analogs in …

The pharmacological effects (ie, inhibition of endocrine secretion and cell proliferation)
mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity …

Introduction: Somatostatin and dopamine receptors are both G-protein-coupled receptors.
Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well …

Background: Somatostatin is a tetradecapeptide exerting inhibitory action on endocrine and
exocrine cell secretion and proliferation. Somatostatin receptors (SST) are widely expressed …

Gastroenteropancreatic neuroendocrine neoplasm (GEP‑NEN) is known to overexpress
somatostatin receptors (SSTRs), most commonly SSTR2 and SSTR5. The expression of …

Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the
bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical …

Simple Summary Neuroendocrine neoplasms are highly heterogeneous tumors in terms of
primary origin, molecular landscape, clinical presentation and behavior. To date, several …

Somatostatin acts as an inhibitory peptide of various secretory and proliferative responses.
Its effects are mediated by a family of G-protein-coupled receptors (sst1-5) that can couple to …

Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumors, mainly
localized in the gastrointestinal system. What characterizes NENs is the expression of …